PHARMACOLOGY articles

AHA 2018 | PIONEER-HF: sacubitril/valsartan en insuficiencia cardíaca aguda descompensada

AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure

AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure

Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations and clinical events, according to the PIONEER-HF study presented at the American Heart Association (AHA) Congress Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). The study

Las nuevas guías de dislipemia apoyan la terapia sin estatinas y la búsqueda de calcio coronario

AHA 2018 | New Dyslipidemia Guidelines Support Non-Statin Therapy and Coronary Artery Calcium Screening

While the guidelines do not recommend a specific treatment target, they suggest additional therapy in high-risk patients with LDL 70 mg/dL or higher. These new guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA) start recommending ezetimibe or PCSK9 inhibition in select high-risk patients and proposing noninvasive coronary artery calcium screening

AHA 2018 | El metotrexate como anti inflamatorio no logró mostrar beneficios

AHA 2018 | No Benefits with Methothrexate as Anti-Inflammatory Drug

Low-dose methotrexate (a nonspecific anti-inflammatory agent used for the treatment of rheumatoid arthritis and other autoimmune disorders) did not prevent cardiovascular events in patients with a prior infarction or multivessel coronary artery disease, according to this study presented at the American Heart Association (AHA) Congress and published simultaneously in the New England Journal of Medicine

El Canakinumab reduce las hospitalizaciones por insuficiencia cardíaca en los respondedores

AHA 2018 | Canakinumab Reduces Hospitalization for Cardiac Failure in Respondents

The benefit was dose-dependent reduction, regardless the presence of absence of baseline cardiac failure. Patients with prior MI and hypersensitivity C-reactive protein (hsCRP) showed dose dependent hospitalization reduction for cardiac failure with the new anti-inflammatory drug Canakinumab, according to this study presented at AHA and simultaneously published in Circulation.   The difference between Canakinumab and

Top